查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1466251

白斑症治療藥物市場：治療方法、疾病類型、藥物類型、最終用戶、分銷管道 - 全球預測 2024-2030

Vitiligo Therapeutics Market by Treatment (Light Therapy, Surgical Procedures, Topical Treatment), Disease Type (Nonsegmental Vitiligo, Segmental Vitiligo), Drug Type, End User, Distribution Channel - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年白斑症治療藥物市場規模為14.5億美元，預計2024年將達15.6億美元，2030年將達25.5億美元，複合年成長率為8.43%。

白斑症治療包括各種旨在控制和改善白斑症的醫學治療和策略，白斑症是一種由於黑色素細胞（負責皮膚色素的細胞）喪失而導致皮膚上出現白斑的疾病。該醫療領域包括局部和全身干預、先進的照光治療、外科手術和心理支持。這些治療方法的主要目標是穩定病情、促進色素沉澱並改善白斑症患者的生活品質。隨著尋常性白斑症盛行率的增加，對改進的白斑症治療藥物的需求增加，從而促進了市場的成長。創新治療方法、持續研究以及更有效治療方法的開發正在推動市場擴張。公共和私營部門不斷成長的全球醫療保健支出正在推動更強勁的市場開拓。然而，與先進治療方法相關的高成本可能會阻礙白斑症治療方法進入市場。在某些地區，對白斑的了解和認知有限阻礙了其診斷和治療。此外， Janus激酶 (JAK) 抑制劑等標靶治療的進展為治療包括白斑症在內的自體免疫疾病提供了潛在的機會。在遺傳和生物標記研究的支持下，增加對聯合治療和個人化醫療的研發投資預計也將在未來幾年帶來市場成長的潛力。

主要市場統計
基準年[2023] 14.5億美元
預測年份 [2024] 15.6億美元
預測年份 [2030] 25.5億美元
複合年成長率（%） 8.43%

治療性光療法的重大技術進步

照光治療，例如 UVB照光治療或 PUVA（補骨脂素 + UVA）療法，是白斑症的常見治療方法，包括在醫生的監督下將皮膚暴露在紫外線 (UV) 下。照光治療適合白斑症影響身體大部分部位或局部治療效果不夠有效的患者。手術治療包括植皮、微色素沉著和黑色素細胞移植，以控制穩定的長效白斑。皮膚移植涉及將皮膚的色素區域移植到脫色斑塊上，黑色素細胞移植涉及將健康皮膚的黑色素細胞移植到受影響的區域。局部治療包括將乳霜或軟膏直接塗布在皮膚上。局部治療包括皮質類固醇、Calcineurin抑制劑和其他促進或預防色素沉著的藥物。局部治療最適合患有小型、局限性白斑症的患者，並且通常建議用於不適合照光治療或手術治療的敏感區域的白斑患者。

節段性白斑疾病類型的盛行率增加

非節段性白斑症是最常見的形式，有多種治療選擇，包括局部用藥、照光治療、全身治療和手術。非節段性白斑通常是進行性的，治療方法旨在阻止進展、實現色素沉著並提供持久的效果。節段性白斑較為局限，往往是只影響身體一側的局限性白斑。節段性白斑症一般起病較快，通常在幾年內穩定下來，治療方法通常包括早期療育和標靶治療。

藥物類型 JAK 抑制劑在白斑症治療中具有良好的治療作用

Calcineurin抑制劑，包括Tacrolimus和Pimecrolimus，是局部免疫調節劑，擴大用於治療白斑症，特別是在對類固醇敏感的區域，例如臉部和頸部。Calcineurin酶抑制劑透過抑制Calcineurin發揮作用，從而降低皮膚中 T 細胞的活性，並可能導致色素脫失。對於尋求節省類固醇選擇或色素脫失較小且局部的患者來說，Calcineurin抑制劑是首選。Calcipotriene(Calcipotriene) 是一種合成維生素 D3 類似物，可促進黑色素細胞增殖並促進皮膚色素沉著。皮質類固醇經常用於治療白斑症，以減少發炎並阻止疾病的進展。皮質類固醇有外用、口服和注射形式，適用於更廣泛的脫色。 JAK抑制劑是一種針對Janus激酶（JAK）途徑的治療白斑症的新型藥物，該路徑在白斑的發病機制中發揮重要作用。託法替尼和魯索替尼等 JAK 抑制劑在臨床試驗中在誘導色素沉著過度方面顯示出有希望的結果。由於 JAK 抑制劑可以口服給藥，因此它們可能是更廣泛的白斑症全身治療的一種選擇。

最終使用者：由於成本效益，對皮膚診所的偏好增加

能夠提供綜合護理和先進治療方案的醫院在白斑藥物市場中佔有很大佔有率。醫院擁有專門的皮膚科，擁有最先進的技術和執行複雜白斑症治療的專家團隊。皮膚診所專注於皮膚病治療，通常提供個人化服務，這對尋求有針對性的白斑症治療的患者很有吸引力。透過專注於門診治療並盡量減少侵入性手術，皮膚診所比醫院更方便且更具成本效益。

分銷通路：網路藥局通路呈現成長趨勢

白斑症治療藥物的主要分銷管道是醫院藥房，患者在諮詢和治療後可以立即直接獲得處方藥。醫院藥局的選擇取決於需要，特別是為了方便在皮膚科手術或與白斑症相關的醫院治療後立即獲得藥物。網路藥局由於購買藥品的便利性和隱私性，已成為白斑症治療藥物的重要通路。與實體藥局相比，由於管理成本較低，線上藥局也提供有競爭力的價格。零售藥局是分銷白斑症治療藥物的傳統且普及的管道。零售藥局通常是首選，因為它們可以隨時獲得非處方藥和個人化服務。

區域洞察

在美國，白斑症的盛行率不斷上升，導致白斑症治療的消費者基礎不斷擴大。主要製藥公司的存在和強大的醫療保健基礎設施正在支持美洲地區的市場擴張。歐盟 (EU) 是一個提供多種白斑症治療和先進治療解決方案的市場。歐洲研究經費的增加有助於擴大白斑症治療的管道。由於不同的經濟條件、醫療基礎設施和對白斑的文化認知，中東和非洲市場非常複雜。由於意識的提高、醫療保健系統的改善和可支配收入的增加，亞太地區正在見證巨大的成長潛力。亞太地區的參與者正在與全球相關人員合作，以提高對開拓區域市場的滲透率，從而推動亞太地區的市場成長。

FPNV定位矩陣

FPNV定位矩陣對於評估白斑症治療藥物市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標，以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估，供應商被分為四個成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對白斑症治療藥物市場供應商的現狀進行深入而深入的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻，以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外，該分析還提供了對該行業競爭特徵的寶貴見解，包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略，從而在市場上獲得競爭優勢。

本報告在以下方面提供了寶貴的見解：

1. 市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2. 市場開拓：我們深入研究利潤豐厚的新興市場，並分析其在成熟細分市場的滲透率。

3. 市場多元化：提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。

4. 競爭評估和情報：對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況和製造能力進行全面評估。

5. 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告解決了以下關鍵問題：

1.白斑症治療藥物市場規模及預測如何？

2.白斑症治療藥物市場預測期間需要考慮投資的產品、細分市場、應用和領域有哪些？

3.白斑症治療藥物市場的技術趨勢和法規結構是什麼？

4.白斑症治療藥物市場主要供應商的市場佔有率為何？

5.進入白斑症治療藥物市場的合適型態和策略手段是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 全球白斑症病例不斷增加
      • 提高人們對有效治療方法的認知
    • 抑制因素
      • 白斑症治療和產品召回的潛在風險
    • 機會
      • 增加臨床試驗和研發活動，有效開發白斑治療藥物
      • 白斑症治療藥物的有利報銷方案
    • 任務
      • 發展中地區的治療方法有限，且有與白斑藥物相關的副作用風險。
  • 市場區隔分析
    • 治療：光療的重大技術進步
    • 疾病類型：節段性白斑症盛行率上升
    • 藥物類型：JAK抑制劑治療白斑效果良好
    • 最終用戶：由於成本效益，在皮膚科診所中越來越受歡迎
    • 分銷通路：網路藥局通路呈現成長趨勢
  • 市場趨勢分析
    • 白斑擁有強大的研發基礎設施，並且正在美洲進行臨床試驗以發現新的治療方法。
    • 認知宣傳活動和治療組合的改進導致先進的白斑症治療在亞太地區獲得核准
    • 歐洲、中東和非洲地區的白斑症盛行率不斷上升，增加了對新治療方法的需求
  • 高通膨的累積效應
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 法規結構分析

第6章 依治療分類的白斑症治療藥物市場

  • 光療
  • 手術過程
  • 局部治療

第7章白斑症治療藥物市場：依疾病類型

  • 非節段性白斑
  • 節段性白斑

第8章白斑症治療藥物市場依藥物類型分類

  • Calcineurin抑制劑
  • Calcipotriene
  • 皮質類固醇
  • JAK抑制劑

第9章白斑症治療藥物市場：依最終用戶分類

  • 醫院
  • 皮膚科診所

第10章白斑症治療藥物市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第11章 北美、南美白斑症治療藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第12章亞太地區白斑症治療藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第13章歐洲、中東和非洲白斑症治療藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • Clinuvel 開始白斑第三階段國際研究
    • 艾伯維 (AbbVie) 宣布Upadacitinib(Rinvoc) 在白斑症 2 期臨床試驗中達到主要終點，並將計畫推進至 3 期
    • Glenmark Pharmaceuticals 0.03%Tacrolimus軟膏獲得 sANDA核准
    • AVITA Medical 宣布 FDA核准RECELL 用於白斑症患者的皮膚色素沉著治療
    • Insight 宣布歐盟委員會核准Opzella (Ruxolitinib) 霜用於治療成人和青少年臉部非節段性白斑
    • 麻省理工學院陳學院 (MIT Chan College) 向 Ardena Therapeutics 授予 siRNA 化學許可，用於開發皮膚病治療方法
    • 加拿大衛生署核准Edesa Biotech 的白斑症治療試驗
    • Ahamne Biosciences 完成白斑症治療第一期臨床試驗
    • Insight 宣布與 Medixie 支持的 Viralis Therapeutics 就抗 IL-15RB 單株抗體 Auremolimab (VM6) 達成收購協議
    • Almirall 和 Inselm Transfer 簽署白斑症調查合約

第15章競爭產品組合

  • 主要企業簡介
  • 主要產品系列
Product Code: MRR-742BD51851D2

[183 Pages Report] The Vitiligo Therapeutics Market size was estimated at USD 1.45 billion in 2023 and expected to reach USD 1.56 billion in 2024, at a CAGR 8.43% to reach USD 2.55 billion by 2030.

Vitiligo therapeutics encompasses a range of medical treatments and strategies aimed at managing and remedying vitiligo, a condition characterized by the development of white patches on the skin due to the loss of melanocytes, the cells responsible for skin pigment. This field of medicine includes both topical and systemic interventions, advanced light-based therapies, surgical procedures, and psychological support. The primary goals of these therapeutic approaches are to stabilize the condition, encourage repigmentation, and improve the quality of life for individuals affected by vitiligo. The rising prevalence of vitiligo conditions is enhancing the need for improved vitiligo therapeutics, contributing to the market growth. Innovative therapies, ongoing research, and developments in more effective treatments fuel market expansion. The higher healthcare spending worldwide by the public and private sectors empowers more robust market development. However, high costs associated with advanced therapeutics may hinder the market accessibility of vitiligo therapies. Limited understanding and awareness of vitiligo in certain geographical regions impede diagnosis and treatment of vitiligo. Moreover, the advancements in targeted therapies, such as Janus kinase (JAK) inhibitors, show potential opportunities in treating autoimmune disorders, including vitiligo. The increased investment in R&D for combination therapies and personalized medicine, underpinned by genetic and biomarker studies, is also anticipated to present the potential for market growth in upcoming years.

KEY MARKET STATISTICS
Base Year [2023] USD 1.45 billion
Estimated Year [2024] USD 1.56 billion
Forecast Year [2030] USD 2.55 billion
CAGR (%) 8.43%

Treatment: Significant technological advancements in light therapies

Light therapy such as UVB phototherapy and PUVA (psoralen plus UVA) therapy are common treatments for vitiligo, which involves exposing the skin to ultraviolet (UV) light under medical supervision. Light therapies are preferred for patients with significant portions of their body afflicted with vitiligo or those who have not responded adequately to topical treatments. Surgical procedures include skin grafting, micro pigmentation, and melanocyte transplantation to manage stable and long-acting vitiligo disorder. Skin grafting involves transferring skin from pigmented areas to depigmented patches, whereas melanocyte transplantation involves transferring melanocytes from healthy skin to the affected areas. Topical treatment constitutes creams and ointments applied directly to the skin. Topical treatment includes corticosteroids, calcineurin inhibitors, and other agents to promote pigmentation or stop depigmentation. Topical treatments are most suitable for patients with small, localized patches of vitiligo and are often recommended for those with the disease affecting sensitive areas that may not be ideal for light therapy or surgical options.

Disease Type: Rising prevalence of segmental vitiligo disorder

Nonsegmental vitiligo is the most common form, with broad treatment options, including topical agents, phototherapy, systemic treatments, and surgical options. Nonsegmental vitiligo is often progressive, and treatment approaches aim to halt progression, achieve repigmentation, and offer sustainable results. Segmental vitiligo tends to be more localized and sectorial, impacting only one side of the body. Segmental vitiligo typically has an earlier onset and often stabilizes within a few years, with the treatment approach commonly involving early intervention with targeted therapies.

Drug Type: Promising therapeutic action of JAK inhibitors for vitiligo management

Calcineurin inhibitors, including tacrolimus and pimecrolimus, are topical immunomodulators that have been increasingly used for treating vitiligo, especially for areas sensitive to steroid effects, such as the face and neck. Calcineurin inhibitors act by inhibiting calcineurin, which subsequently reduces the activity of T-cells in the skin and can cause pigment loss. Calcineurin inhibitor drugs are a preferred option for patients looking for steroid-sparing alternatives and for those with smaller, localized areas of depigmentation. Calcipotriene, a synthetic vitamin D3 analogue, promotes melanocyte multiplication and enhances skin repigmentation. Corticosteroids are frequently prescribed in the treatment of vitiligo to reduce inflammation and to attempt to halt the progression of the disease. Corticosteroids are available in topical, oral, and injectable forms and are suited for more widespread areas of pigment loss. JAK inhibitors represent a newer class of drug in vitiligo management that targets the Janus kinase (JAK) pathway, which is crucial in the pathogenesis of vitiligo. JAK inhibitors, such as tofacitinib and ruxolitinib, have shown promising results in clinical trials for inducing repigmentation. Due to their oral route of administration, JAK inhibitors could offer a systemic treatment option for more extensive vitiligo.

End User: Growing preference for skin clinics due to cost effectiveness

Hospitals hold a substantial share in the vitiligo therapeutics market due to their ability to offer comprehensive care and advanced treatment options. Hospitals have specialized dermatology departments equipped with cutting-edge technologies and a team of experts to administer complex vitiligo treatments. Skin clinics specialize in dermatological care and often offer personalized services, which make them appealing for patients seeking targeted vitiligo treatment. Skin clinics provide improved accessibility and cost-effectiveness than hospital settings, focusing on outpatient care and minimal use of invasive procedures.

Distribution Channel: Rising inclination towards online pharmacy channels

Hospital pharmacies represent a primary distribution channel for vitiligo therapeutics where patients have direct access to prescribed medications immediately after consultation or treatment. The need-based preference for hospital pharmacies stems from the convenience of immediate access to medication, especially after dermatological procedures or inpatient care related to vitiligo. Online pharmacies have become important as a distribution channel for vitiligo therapeutics due to the convenience and privacy of medicine purchases. Online pharmacies also provide competitive pricing due to lower overhead costs compared to brick-and-mortar pharmacies. Retail pharmacies remain a traditional and widespread channel for distributing vitiligo therapeutics. The preference for retail pharmacies is often due to the immediate availability of over-the-counter treatments and personalized service.

Regional Insights

In the Americas region, the United States has observed a substantial consumer base for vitiligo therapeutics due to the rising prevalence of vitiligo disease. The presence of key pharmaceutical companies and robust healthcare infrastructure propels the market forward in the Americas region. The European Union presents a diverse market with varying access to vitiligo treatments and advanced therapeutic solutions. The increased research funding within the European region has contributed to a growing pipeline of vitiligo therapies. The Middle East and Africa markets are complex due to the variation in economic status, healthcare infrastructure, and cultural perceptions of vitiligo. The Asia-Pacific region has witnessed significant growth potential due to increasing awareness, improving healthcare systems, and rising disposable incomes. The players in the APAC region are collaborating with global stakeholders to enhance the market penetration into untapped regional markets, driving market growth in the APAC region.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Vitiligo Therapeutics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Vitiligo Therapeutics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Vitiligo Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Accord Healthcare, Inc., Ahammune Biosciences Pvt. Ltd., Amgen Inc., Arcutis Biotherapeutics, Inc., Array Skin Therapy, Astellas Pharma, Inc., AVITA Medical, Inc., Bausch Health Companies Inc., Biocon Limited, Clarify Health Solutions, Inc., Clinuvel Pharmaceuticals Ltd., Dermavant Sciences, Inc., Dr. Reddy's Laboratories Ltd., Edesa Biotech, Inc., Glenmark Pharmaceuticals Limited, Incyte Corporation, ISSAR pharmaceuticals Pvt. Ltd., JN Biosciences LLC, Kernel Medical Equipment Co.,LTD, Koninklijke Philips N.V., Merck KGaA, Mylan N.V. by Viatris Inc., Nova Dermatology, Novartis AG, Organic Care Australia Pty Ltd., Panacea Biotec Limited, Pfizer Inc., Philadelphia Pharmaceuticals, Pierre Fabre S.A, Puneet Laboratories Pvt. Ltd., SESDERMA, S.L, SOMA Skin & Laser, LLC, Stem Cell Care India, Strides Pharma Science Limited, Temprian Therapeutics Inc., TeVido BioDevices, The Daavlin Company, UNIZA Group, and Vyne Therapeutics, Inc..

Market Segmentation & Coverage

This research report categorizes the Vitiligo Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Treatment
    • Light Therapy
    • Surgical Procedures
      • Cell Transplant
      • Skin Graft
    • Topical Treatment
  • Disease Type
    • Nonsegmental Vitiligo
    • Segmental Vitiligo
  • Drug Type
    • Calcineurin Inhibitors
    • Calcipotriene
    • Corticosteroids
    • JAK inhibitor
  • End User
    • Hospitals
    • Skin Clinics
  • Distribution Channel
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Vitiligo Therapeutics Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Vitiligo Therapeutics Market?

3. What are the technology trends and regulatory frameworks in the Vitiligo Therapeutics Market?

4. What is the market share of the leading vendors in the Vitiligo Therapeutics Market?

5. Which modes and strategic moves are suitable for entering the Vitiligo Therapeutics Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising cases of vitiligo across the globe
      • 5.1.1.2. Growing awareness regarding the availability of effective treatments
    • 5.1.2. Restraints
      • 5.1.2.1. Potential risk of vitiligo drug and product recall
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing number of clinical trials and R&D activities for the development of efficient vitiligo therapeutics
      • 5.1.3.2. Favorable reimbursement scenario for vitiligo therapeutics
    • 5.1.4. Challenges
      • 5.1.4.1. Limited reach of therapies in developing regions coupled with the risk of adverse effects associated with vitiligo therapeutics
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Treatment: Significant technological advancements in light therapies
    • 5.2.2. Disease Type: Rising prevalence of segmental vitiligo disorder
    • 5.2.3. Drug Type: Promising therapeutic action of JAK inhibitors for vitiligo management
    • 5.2.4. End User: Growing preference for skin clinics due to cost effectiveness
    • 5.2.5. Distribution Channel: Rising inclination towards online pharmacy channels
  • 5.3. Market Trend Analysis
    • 5.3.1. Strong research and development infrastructure for vitiligo with clinical trials underway to discover new treatment modalities in the Americas
    • 5.3.2. Approvals for advanced vitiligo therapeutics in APAC backed by improved awareness campaigns and therapeutics portfolios
    • 5.3.3. Elevating prevalence of vitiligo creating need for novel therapeutics in the EMEA region
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework Analysis

6. Vitiligo Therapeutics Market, by Treatment

  • 6.1. Introduction
  • 6.2. Light Therapy
  • 6.3. Surgical Procedures
  • 6.4. Topical Treatment

7. Vitiligo Therapeutics Market, by Disease Type

  • 7.1. Introduction
  • 7.2. Nonsegmental Vitiligo
  • 7.3. Segmental Vitiligo

8. Vitiligo Therapeutics Market, by Drug Type

  • 8.1. Introduction
  • 8.2. Calcineurin Inhibitors
  • 8.3. Calcipotriene
  • 8.4. Corticosteroids
  • 8.5. JAK inhibitor

9. Vitiligo Therapeutics Market, by End User

  • 9.1. Introduction
  • 9.2. Hospitals
  • 9.3. Skin Clinics

10. Vitiligo Therapeutics Market, by Distribution Channel

  • 10.1. Introduction
  • 10.2. Hospital Pharmacies
  • 10.3. Online Pharmacies
  • 10.4. Retail Pharmacies

11. Americas Vitiligo Therapeutics Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Vitiligo Therapeutics Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Vitiligo Therapeutics Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Clinuvel Starts Global Phase III Vitiligo Study
    • 14.3.2. AbbVie Announces Upadacitinib (RINVOQ) Met the Primary Endpoint in Phase 2 Clinical Trial of Vitiligo as Program Advances to Phase 3
    • 14.3.3. Glenmark Pharmaceuticals Receives sANDA Approval for Tacrolimus Ointment, 0.03%
    • 14.3.4. AVITA Medical Announces FDA Approval of RECELL for Skin Repigmentation in Vitiligo Patients
    • 14.3.5. Incyte Announces European Commission Approval Of Opzelura (Ruxolitinib) Cream For The Treatment Of Non-Segmental Vitiligo With Facial Involvement In Adults And Adolescents
    • 14.3.6. UMass Chan Licensed siRNA chemistry to Aldena Therapeutics To Develop Therapies For Dermatological Diseases
    • 14.3.7. Health Canada Grants Approval for Edesa Biotech's Vitiligo Therapy Trial
    • 14.3.8. Ahammune Biosciences Completes Phase I Clinical Trial For Vitiligo Drug
    • 14.3.9. Incyte Announces Agreement To Acquire Medicxi-Backed Villaris Therapeutics And Auremolimab (VM6), An Anti-IL-15RB Monoclonal Antibody
    • 14.3.10. Almirall, Inserm Transfert Enter Agreement for Vitiligo Research

15. Competitive Portfolio

  • 15.1. Key Company Profiles
  • 15.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. VITILIGO THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. VITILIGO THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. VITILIGO THERAPEUTICS MARKET DYNAMICS
  • FIGURE 7. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 14. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 16. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. AMERICAS VITILIGO THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. AMERICAS VITILIGO THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. UNITED STATES VITILIGO THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 20. UNITED STATES VITILIGO THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. ASIA-PACIFIC VITILIGO THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. ASIA-PACIFIC VITILIGO THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA VITILIGO THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA VITILIGO THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 25. VITILIGO THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 26. VITILIGO THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. VITILIGO THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY LIGHT THERAPY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY LIGHT THERAPY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY CELL TRANSPLANT, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY CELL TRANSPLANT, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY SKIN GRAFT, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY SKIN GRAFT, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY TOPICAL TREATMENT, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY TOPICAL TREATMENT, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY NONSEGMENTAL VITILIGO, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY NONSEGMENTAL VITILIGO, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY SEGMENTAL VITILIGO, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY SEGMENTAL VITILIGO, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY CALCINEURIN INHIBITORS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY CALCINEURIN INHIBITORS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY CALCIPOTRIENE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY CALCIPOTRIENE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY JAK INHIBITOR, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY JAK INHIBITOR, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY SKIN CLINICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY SKIN CLINICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 43. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 44. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 45. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 46. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 47. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 48. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 49. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 50. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 51. AMERICAS VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 52. AMERICAS VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 53. AMERICAS VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2023 (USD MILLION)
  • TABLE 54. AMERICAS VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2024-2030 (USD MILLION)
  • TABLE 55. AMERICAS VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 56. AMERICAS VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 57. AMERICAS VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 58. AMERICAS VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 59. AMERICAS VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 60. AMERICAS VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 61. AMERICAS VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 62. AMERICAS VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 63. AMERICAS VITILIGO THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 64. AMERICAS VITILIGO THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 65. ARGENTINA VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 66. ARGENTINA VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 67. ARGENTINA VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2023 (USD MILLION)
  • TABLE 68. ARGENTINA VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2024-2030 (USD MILLION)
  • TABLE 69. ARGENTINA VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 70. ARGENTINA VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 71. ARGENTINA VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 72. ARGENTINA VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 73. ARGENTINA VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 74. ARGENTINA VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 75. ARGENTINA VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 76. ARGENTINA VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 77. BRAZIL VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 78. BRAZIL VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 79. BRAZIL VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2023 (USD MILLION)
  • TABLE 80. BRAZIL VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2024-2030 (USD MILLION)
  • TABLE 81. BRAZIL VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 82. BRAZIL VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 83. BRAZIL VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 84. BRAZIL VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 85. BRAZIL VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 86. BRAZIL VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 87. BRAZIL VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 88. BRAZIL VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 89. CANADA VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 90. CANADA VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 91. CANADA VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2023 (USD MILLION)
  • TABLE 92. CANADA VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2024-2030 (USD MILLION)
  • TABLE 93. CANADA VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 94. CANADA VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 95. CANADA VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 96. CANADA VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 97. CANADA VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 98. CANADA VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 99. CANADA VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 100. CANADA VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 101. MEXICO VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 102. MEXICO VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 103. MEXICO VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2023 (USD MILLION)
  • TABLE 104. MEXICO VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2024-2030 (USD MILLION)
  • TABLE 105. MEXICO VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 106. MEXICO VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 107. MEXICO VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 108. MEXICO VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 109. MEXICO VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 110. MEXICO VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 111. MEXICO VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 112. MEXICO VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 113. UNITED STATES VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 114. UNITED STATES VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 115. UNITED STATES VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2023 (USD MILLION)
  • TABLE 116. UNITED STATES VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2024-2030 (USD MILLION)
  • TABLE 117. UNITED STATES VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 118. UNITED STATES VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 119. UNITED STATES VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 120. UNITED STATES VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 121. UNITED STATES VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 122. UNITED STATES VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 123. UNITED STATES VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 124. UNITED STATES VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 125. UNITED STATES VITILIGO THERAPEUTICS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 126. UNITED STATES VITILIGO THERAPEUTICS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2023 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2024-2030 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC VITILIGO THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC VITILIGO THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 141. AUSTRALIA VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 142. AUSTRALIA VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 143. AUSTRALIA VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2023 (USD MILLION)
  • TABLE 144. AUSTRALIA VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2024-2030 (USD MILLION)
  • TABLE 145. AUSTRALIA VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 146. AUSTRALIA VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 147. AUSTRALIA VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 148. AUSTRALIA VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 149. AUSTRALIA VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 150. AUSTRALIA VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 151. AUSTRALIA VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 152. AUSTRALIA VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 153. CHINA VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 154. CHINA VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 155. CHINA VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2023 (USD MILLION)
  • TABLE 156. CHINA VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2024-2030 (USD MILLION)
  • TABLE 157. CHINA VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 158. CHINA VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 159. CHINA VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 160. CHINA VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 161. CHINA VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 162. CHINA VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 163. CHINA VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 164. CHINA VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 165. INDIA VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 166. INDIA VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 167. INDIA VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2023 (USD MILLION)
  • TABLE 168. INDIA VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2024-2030 (USD MILLION)
  • TABLE 169. INDIA VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 170. INDIA VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 171. INDIA VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 172. INDIA VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 173. INDIA VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 174. INDIA VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 175. INDIA VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 176. INDIA VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 177. INDONESIA VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 178. INDONESIA VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 179. INDONESIA VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2023 (USD MILLION)
  • TABLE 180. INDONESIA VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2024-2030 (USD MILLION)
  • TABLE 181. INDONESIA VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 182. INDONESIA VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 183. INDONESIA VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 184. INDONESIA VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 185. INDONESIA VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 186. INDONESIA VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 187. INDONESIA VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 188. INDONESIA VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 189. JAPAN VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 190. JAPAN VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 191. JAPAN VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2023 (USD MILLION)
  • TABLE 192. JAPAN VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2024-2030 (USD MILLION)
  • TABLE 193. JAPAN VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 194. JAPAN VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 195. JAPAN VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 196. JAPAN VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 197. JAPAN VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 198. JAPAN VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 199. JAPAN VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 200. JAPAN VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 201. MALAYSIA VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 202. MALAYSIA VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 203. MALAYSIA VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2023 (USD MILLION)
  • TABLE 204. MALAYSIA VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2024-2030 (USD MILLION)
  • TABLE 205. MALAYSIA VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 206. MALAYSIA VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 207. MALAYSIA VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 208. MALAYSIA VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 209. MALAYSIA VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 210. MALAYSIA VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 211. MALAYSIA VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 212. MALAYSIA VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 213. PHILIPPINES VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 214. PHILIPPINES VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 215. PHILIPPINES VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2023 (USD MILLION)
  • TABLE 216. PHILIPPINES VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2024-2030 (USD MILLION)
  • TABLE 217. PHILIPPINES VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 218. PHILIPPINES VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 219. PHILIPPINES VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 220. PHILIPPINES VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 221. PHILIPPINES VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 222. PHILIPPINES VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 223. PHILIPPINES VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 224. PHILIPPINES VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 225. SINGAPORE VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 226. SINGAPORE VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 227. SINGAPORE VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2023 (USD MILLION)
  • TABLE 228. SINGAPORE VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2024-2030 (USD MILLION)
  • TABLE 229. SINGAPORE VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 230. SINGAPORE VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 231. SINGAPORE VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 232. SINGAPORE VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 233. SINGAPORE VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 234. SINGAPORE VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 235. SINGAPORE VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 236. SINGAPORE VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 237. SOUTH KOREA VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 238. SOUTH KOREA VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 239. SOUTH KOREA VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2023 (USD MILLION)
  • TABLE 240. SOUTH KOREA VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2024-2030 (USD MILLION)
  • TABLE 241. SOUTH KOREA VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 242. SOUTH KOREA VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 243. SOUTH KOREA VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 244. SOUTH KOREA VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 245. SOUTH KOREA VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 246. SOUTH KOREA VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 247. SOUTH KOREA VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 248. SOUTH KOREA VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 249. TAIWAN VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 250. TAIWAN VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 251. TAIWAN VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2023 (USD MILLION)
  • TABLE 252. TAIWAN VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2024-2030 (USD MILLION)
  • TABLE 253. TAIWAN VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 254. TAIWAN VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 255. TAIWAN VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 256. TAIWAN VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 257. TAIWAN VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 258. TAIWAN VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 259. TAIWAN VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 260. TAIWAN VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 261. THAILAND VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 262. THAILAND VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 263. THAILAND VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2023 (USD MILLION)
  • TABLE 264. THAILAND VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2024-2030 (USD MILLION)
  • TABLE 265. THAILAND VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 266. THAILAND VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 267. THAILAND VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 268. THAILAND VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 269. THAILAND VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 270. THAILAND VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 271. THAILAND VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 272. THAILAND VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 273. VIETNAM VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 274. VIETNAM VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 275. VIETNAM VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2023 (USD MILLION)
  • TABLE 276. VIETNAM VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2024-2030 (USD MILLION)
  • TABLE 277. VIETNAM VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 278. VIETNAM VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 279. VIETNAM VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 280. VIETNAM VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 281. VIETNAM VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 282. VIETNAM VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 283. VIETNAM VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 284. VIETNAM VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 285. EUROPE, MIDDLE EAST & AFRICA VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 286. EUROPE, MIDDLE EAST & AFRICA VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 287. EUROPE, MIDDLE EAST & AFRICA VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2023 (USD MILLION)
  • TABLE 288. EUROPE, MIDDLE EAST & AFRICA VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2024-2030 (USD MILLION)
  • TABLE 289. EUROPE, MIDDLE EAST & AFRICA VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 290. EUROPE, MIDDLE EAST & AFRICA VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 291. EUROPE, MIDDLE EAST & AFRICA VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 292. EUROPE, MIDDLE EAST & AFRICA VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 293. EUROPE, MIDDLE EAST & AFRICA VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 294. EUROPE, MIDDLE EAST & AFRICA VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 295. EUROPE, MIDDLE EAST & AFRICA VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 296. EUROPE, MIDDLE EAST & AFRICA VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 297. EUROPE, MIDDLE EAST & AFRICA VITILIGO THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 298. EUROPE, MIDDLE EAST & AFRICA VITILIGO THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 299. DENMARK VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 300. DENMARK VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 301. DENMARK VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2023 (USD MILLION)
  • TABLE 302. DENMARK VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2024-2030 (USD MILLION)
  • TABLE 303. DENMARK VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 304. DENMARK VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 305. DENMARK VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 306. DENMARK VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 307. DENMARK VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 308. DENMARK VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 309. DENMARK VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 310. DENMARK VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 311. EGYPT VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 312. EGYPT VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 313. EGYPT VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2023 (USD MILLION)
  • TABLE 314. EGYPT VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2024-2030 (USD MILLION)
  • TABLE 315. EGYPT VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 316. EGYPT VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 317. EGYPT VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 318. EGYPT VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 319. EGYPT VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 320. EGYPT VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 321. EGYPT VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 322. EGYPT VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 323. FINLAND VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 324. FINLAND VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 325. FINLAND VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2023 (USD MILLION)
  • TABLE 326. FINLAND VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2024-2030 (USD MILLION)
  • TABLE 327. FINLAND VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 328. FINLAND VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 329. FINLAND VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 330. FINLAND VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 331. FINLAND VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 332. FINLAND VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 333. FINLAND VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 334. FINLAND VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 335. FRANCE VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 336. FRANCE